Skip to content

Study · Animal study (in vivo) · rat · 1992

2 results

Potent gonadotropin releasing hormone antagonists with low histamine-releasing activity.

Nestor JJ Jr, Tahilramani R, Ho TL, Goodpasture JC, Vickery BH, Ferrandon P

Journal of medicinal chemistry1 Oct 1992Cited by 21 (Europe PMC)

PMID1279174 (opens in a new tab)DOI10.1021/jm00099a023 (opens in a new tab)PepBankPUB-01279174
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Activity measurement

    In rats, ganirelix acetate had an ovulation-suppression ED50 of 0.29 microgram/rat.

    In plain wordsIn rats, ganirelix acetate had an ovulation-suppression ED50 of 0.29 microgram/rat.

    Peptide
    Ganirelix
    Outcome
    Not applicableOvulation suppression ED50
    Study

    ratn: not reported in source

    Outcome group
    Sex hormones and fertility · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    ED50
    0.29 microgram/rat
    ovulation suppression

    Source sentences

    Summary
    These compounds had high potency for ovulation suppression and low histamine-releasing potency in vitro (ED50 = 0.6, 0.29 microgram/rat and EC50 = 196, 13 micrograms/mL, respectively).
    1 context sentence
    Summary · context
    Two compounds were considered for clinical evaluation: [N-Ac-D-Nal(2)1,D-pCl-Phe2,D-Pal(3)3,6,hArg(Et)2(8),D-Ala10] GnRH and [N-Ac-D-Nal(2)1,D-pCl-Phe2,D-Pal(3)3,D-hArg(Et)2(6),hArg(Et) 2(8),D- Ala10]GnRH (ganirelix acetate).
  2. 02LabIn vitro (cells)Activity measurement

    In vitro, ganirelix acetate had a histamine-release EC50 of 13 micrograms/mL.

    In plain wordsIn lab tests, ganirelix acetate had a histamine-release EC50 of 13 micrograms/mL.

    Peptide
    Ganirelix
    Outcome
    Not applicableHistamine release EC50
    Study

    n: not reported in source

    Outcome group
    Adverse events · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    EC50
    13 micrograms/mL
    histamine release

    Source sentences

    Summary
    These compounds had high potency for ovulation suppression and low histamine-releasing potency in vitro (ED50 = 0.6, 0.29 microgram/rat and EC50 = 196, 13 micrograms/mL, respectively).
    1 context sentence
    Summary · context
    Two compounds were considered for clinical evaluation: [N-Ac-D-Nal(2)1,D-pCl-Phe2,D-Pal(3)3,6,hArg(Et)2(8),D-Ala10] GnRH and [N-Ac-D-Nal(2)1,D-pCl-Phe2,D-Pal(3)3,D-hArg(Et)2(6),hArg(Et) 2(8),D- Ala10]GnRH (ganirelix acetate).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.